The investment community is grappling with a puzzling disconnect as Hims & Hers shares continue their downward trajectory despite the company reporting what appears to be exceptionally strong operational results for the third quarter of 2025. This divergence between fundamental business performance and market valuation has left analysts searching for explanations.
Regulatory Headwinds Cloud Growth Narrative
While the company’s core business demonstrates remarkable vitality, significant regulatory challenges have emerged that may be weighing on investor sentiment. In September 2025, the Food and Drug Administration issued a warning letter to the telehealth provider, followed shortly by an investigation launched by the Federal Trade Commission. These regulatory developments present potential obstacles to the company’s aggressive expansion strategy.
Adding complexity to the regulatory landscape are ongoing discussions with pharmaceutical giant Novo Nordisk regarding a potential partnership involving Wegovy offerings. Though no definitive agreement has been reached, such a collaboration could either amplify regulatory scrutiny or potentially accelerate the company’s growth trajectory, creating uncertainty that markets typically dislike.
Impressive Growth Metrics Mask Margin Concerns
The company’s operational achievements for Q3 2025 are undeniably robust. Revenue surged by an impressive 49% to reach $599 million, substantially exceeding market expectations. The subscriber base expanded significantly to 2.47 million users, while monthly revenue per customer climbed 19% to $80.
However, beneath these strong top-line figures lies a concerning trend in profitability metrics. The gross margin contracted from 79% to 74%, signaling potential pressure on the company’s earnings capacity. This margin compression stems from increased costs associated with new service offerings and adjustments to shipping frequencies, highlighting that record revenues don’t necessarily translate to maintained profitability.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Strategic Expansion Amid Market Uncertainty
Undeterred by these challenges, Hims & Hers continues to execute an ambitious growth strategy. The July 2025 acquisition of ZAVA opened access to European markets with over 200 million potential customers. The company has already established presence in Germany, Ireland, and France, with Canadian market entry preparations underway.
Beyond geographical diversification, the company is broadening its therapeutic focus. New treatment areas including menopause, perimenopause, and testosterone deficiency are expanding the company’s addressable market while creating a business model more resilient to seasonal fluctuations.
Investor Dilemma: Opportunity or Omen?
Company leadership remains optimistic, reaffirming ambitious 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. For the current fiscal year, management maintains growth projections between 58-59%.
Despite these confident forecasts and strong operational metrics, market participants remain cautious. The stock currently trades approximately 46% below its yearly peak, creating a stark contrast between corporate performance and market valuation. This divergence presents investors with a critical question: does this represent a compelling buying opportunity in a fundamentally strong company, or are markets correctly pricing in risks not immediately visible in the financial statements? The answer to this question will likely determine the stock’s direction in the coming weeks.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 10 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 10.
Hims & Hers: Buy or sell? Read more here...
